


CLAIMS


What is claimed:


1. A compound of formula:


5 ;


5B ;


9B* 


9* 


12* ;

12B* ;

21* ;


21B* ;

23* ; or

23B* ,


or a pharmaceutically acceptable salt or isotopically labeled compound of any one of the foregoing.

2. The compound of claim 1, wherein the compound is:

5 .


or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is:

9B* ;


or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is:

12* ,


or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, wherein the compound is:

21* ,

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, wherein the compound is:

23* ,

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or isotopically labeled compound thereof, or a compound of any one of claims 2-6, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

8. Use of a compound of claim 1, or a pharmaceutically acceptable salt or isotopically labeled compound thereof, or a compound of any one of claims 2-6, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 7 for the treatment or prevention of a disease or disorder.

9. Use of claim 8, wherein the disease or disorder is an NLRP3-related disease or disorder.

10. Use of a compound of claim 1, or a pharmaceutically acceptable salt or isotopically labeled compound thereof, or a compound of any one of claims 2-6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder.

11. The use of claim 8 or claim 10, wherein the disease or disorder is inflammation, an auto-immune disease, a cancer, an infection, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a respiratory disease, a kidney disease, a liver disease, an ocular disease, a skin disease, a lymphatic disease, a rheumatic disease, a psychological disease, graft versus host disease, allodynia, or an NLRP3-related disease in a subject that has been determined to carry a germline or somatic non-silent mutation in NLRP3.

12. The use of claim 8 or claim 10, wherein the disease or disorder is Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, multiple sclerosis, acute kidney disease, a chronic kidney disease, a rare kidney disease, psoriasis, hidradenitis suppurativa, atopic dermatitis, dermatomyositis, Still's disease, juvenile idiopathic arthritis, a cryopyrin-associated autoinflammatory syndrome, refractory epilepsy, stroke, or headache/pain.

13. The use of claim 12, wherein the cryopyrin-associated autoinflammatory syndrome is familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal onset multisystem inflammatory disease.